Browse > Article

Intravenous immunoglobulin for severe gastrointestinal manifestation of Henoch-Schönlein purpura refractory to corticosteroid therapy  

Yang, Hye Ran (Department of Pediatrics, College of Medicine, Seoul National University)
Choi, Won Jung (Department of Pediatrics, College of Medicine, Seoul National University)
Ko, Jae Sung (Department of Pediatrics, College of Medicine, Seoul National University)
Seo, Jeong Kee (Department of Pediatrics, College of Medicine, Seoul National University)
Publication Information
Clinical and Experimental Pediatrics / v.49, no.7, 2006 , pp. 784-789 More about this Journal
Abstract
Purpose : $Henoch-Sch{\ddot{o}}nlein$ purpura(HSP) is a systemic vasculitis involving small vessels of skin, gastrointestinal(GI) tract and kidney. Digestive involvement of HSP can be serious with massive GI bleeding, perforation, and intussusception. However, some patients do not respond to conventional corticosteroid therapy. In this study, we investigated the efficacy of intravenous immunoglobulin (IVIG) for serious digestive manifestations not responding to steroid. Methods : From April 1999 to January 2005, 22 children diagnosed as HSP with severe GI symptoms were included. Initially, all patients were treated with intravenous methylprednisolone. IVIG 2 g/kg of body weight was infused in children refractory to steroid therapy. Clinical data were reviewed retrospectively. Results : Among 22 children, 12 children underwent IVIG therapy. The mean duration of corticosteroid therapy was $5.61{\pm}4.9$ days before IVIG therapy, and 11 of 12 patients experienced disappearance of GI manifestations after the initiation of IVIG infusion. In one patient, IVIG was ineffective in relieving abdominal pain, but melena subsided. Comparison of the duration of hospitalization between IVIG group and corticosteroid group revealed no significant difference($12.8{\pm}7.6$ days vs. $13.2{\pm}7.8$ days, P=0.777). But, the total duration of abdominal pain decreased in IVIG group although the difference between two groups was not significant($8.8{\pm}8.1$ days vs. $14.8{\pm}16.9$ days, P=0.306). Among 10 children treated with steroid only, 2 children were operated for bowel perforation and intussusception. In contrast, there was no perforation in 12 children who underwent IVIG therapy. Conclusion : IVIG could be the alternative therapy to corticosteroids in children with severe digestive manifestations of HSP.
Keywords
$Henoch-Sch{\ddot{o}}nlein$ purpura; Gastrointestinal manifestation; Corticosteroid; Intravenous immunoglobulin; Children;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ruellan A, Khatibi M, Staub T, Martin T, Storck D, Christmann D. Rheumatoic purpura and intravenous immunoglobulins. Rev Med Interne 1997;18:727-9   DOI   ScienceOn
2 Lamireau T, Rebouissoux L, Hehunstre JP. Intravenous immunoglobulin therapy for severe digestive manifestations of Henoch-Schölein purpura. Acta Paediatr 2001;90:1081-2
3 Haroon M. should children with Henoch-Schölein purpura and abdominal pain be treated with steroids? Arch Dis Child 2005;90:1196-8   DOI   ScienceOn
4 Rostoker G, Desvaux-Belghiti D, Pilatte Y, Petit-Phar M, Philippon C, Deforges L, et al. High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schölein purpura. Ann Intern Med 1994;120:476-84   DOI   ScienceOn
5 Choong CK, Beasley SW. Intraabdominal manifestations of Henoch-schölein purpura. J Pediatr Child Health 1998;34: 405-9   DOI   ScienceOn
6 Cho CS, Min JK, Park SH, Yang HI, Lee SH, Choi YJ, et al. Protein losing enteropathy associated with Henoch- Schölein purpura in a patient with rheumatoid arthritis. Scand J Rheumatol 1996;25:334-6   DOI   ScienceOn
7 Kim YO, Lee CY. IV-gamma globulin therapy for severe abdominal pain refractory to steroid therapy. J Korean Society Pediatr Nephrol 1997;1:176-8
8 Saulsbury F. Henoch-Schölein purpura in children. Medicine 1999;78:395-409   DOI   ScienceOn
9 Szer I. Henoch-Schölein purpura when and how to treat. J Rheumatol 1996;23:1661-5
10 Villarreal IR, Ortega O, Vigil A, Gallar P, Oliet A, Garcia- Rubiales A, et al. Henoch-Schölein nephritis. Adverse effect of treatment with intravenous immunoglobulin. Nephrol Dial Transplant 1999;14:795-7   DOI
11 Aries PM, Hellmich B, Gross WL. Intravenous immunoglobulin therapy in vasculitis : speculation or evidence? Clin Rev Allergy Immunol 2005;29:237-46   DOI   ScienceOn
12 Heldrich FJ, Minkin S, Gatdula CL. Intravenous immunoglobulin in Henoch-Schölein purpura : a case study. Md Med J 1993;42:577-9
13 Feldt R, Stickler G. The gastro-intestinal manifestations of anaphylactoid purpura in children. Staff Meetings of the Mayo Clinic 1962;37:465-73
14 Michel BA, Hunder GG, Bloch DA, Calabrese LH. Hypersensitivity vasculitis and Henoch-Schölein purpura : a comparison between the 2 disorders. J Rheumatol 1992;19: 721-8
15 Rostoker G. Schölein-Henoch Purpura in children and adults. BioDrugs 2001;15:99-138   DOI   ScienceOn
16 Kusuda A, Migita K, Tsuboi M, Degawa M, Matsuoka N, Tominaga M, et al. Successful treatment of adult onset Henoch-Schölein purpura nephritis with high dose immunoglobulins. Int Med 1999;38:376-9   DOI
17 Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney-a two-edged sword. Semin Arthritis Rheum 2004;34:593-601   DOI   ScienceOn
18 Hamidou MA, Pottier MA, Dupas B. Intravenous immunoglobulin in Henoch-Schölein purpura. Ann Intern Med 1996;125:1013-4
19 Diaz C. Schölein-Henoch purpura and pancreatitis. Dig Dis Sci 1995;40:750-1   DOI
20 Blanco R, Gonzalez-Gay MA, Ibanez D, Sanchez-Andrade A, Gonzalez-Vela C. Paradoxical and persistent renal impairment in Henoch-Schölein purpura after high-dose immunoglobulin therapy. Nephron 1997;76:247-8   DOI
21 Dwyer JM. Manipulating the immune system with immunoglobulins. N Engl J Med 1992;326:107-14   DOI   ScienceOn
22 Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schölein purpura. Arthritis Rheum 1990;33:1114-21   DOI   ScienceOn
23 Cull D, Rosario V, Lally K, Ratner I, Mahour GH. Surgical implications of Henoch-Schölein purpura. J Pediatr Surg 1990;25:741-3   DOI   ScienceOn
24 Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins. Ann Intern Med 1990;112:278-89   DOI   ScienceOn
25 Lin SJ, Chao HC, Huang JL. Gastrointestinal involvement as the initial manifestation in children with Henoch-Schölein purpura- Clinical analysis of 27 cases. Acta Paediatr Sin 1998;39:186-90
26 Rosenblum N, Winter H. Steroid effects on the course of abdominal pain in children with Henoch-Schölein purpura. Pediatrics 1987;79:1018-21